Nabumetone
Brand names: Relifex
Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) used for the symptomatic relief of pain and inflammation in osteoarthritis and rheumatoid arthritis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a prodrug that is metabolised to an active metabolite which inhibits cyclo-oxygenase, reducing prostaglandin synthesis and thereby decreasing inflammation and pain.
Prescribing in practice
- Carries the class NSAID risks of gastrointestinal ulceration and bleeding, cardiovascular thrombotic events and renal impairment; use the lowest effective dose for the shortest duration and avoid in active peptic ulceration.
- Use with caution in the elderly, in hypertension, heart failure and in those with established cardiovascular or renal disease.
- Avoid concurrent use with other NSAIDs and use caution when combined with anticoagulants, antiplatelets, ACE inhibitors and diuretics.
Monitoring
Monitor blood pressure, renal function and for signs of gastrointestinal bleeding, particularly in older patients and those on long-term therapy.
Counselling the patient
- Take with or after food and report any black stools, vomiting of blood or persistent indigestion.
- Avoid taking other over-the-counter anti-inflammatory medicines at the same time.
Evidence & guidelines
MHRA guidance and NICE recommend using NSAIDs at the lowest effective dose for the shortest period owing to gastrointestinal and cardiovascular risks.
Reference: NICE NG100; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022